4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 10
in 61 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. develops genetic medicines through its proprietary adeno-associated virus vector platform as a NASDAQ-listed Biotechnology company, with development efforts concentrated in ophthalmology, cardiology, and pulmonology. It recorded $85.2 million of revenue in FY2025, and its pipeline spans inherited retinal, cardiac, and pulmonary disease programs.
Today's Snapshot
FDMT closed 3.1% lower at 14.18.
Trading Volume
Below 10d avg (792.5K)
492.5K
vs S&P 500 Today
Underperforming Market
-2.60%
Updated: September 10, 2026 at 12:29 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$10.71 - $14.61Buy
- RSI (14)53.22Neutral
- Stochastic %K (14, 3, 3)28.36Neutral
- MACD Level (12, 26)0.70Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.